Do you want to read an article? Please log in or register.
Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes
Type 2 Diabetes
Related content
Diabetes - GeneralType 2 Diabetes
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Diabetes Care.
Mantovani A, Byrne CD, Bonora E, Targher G
doi: 10.2337/dc17-1902.
COMMENTED
Type 2 DiabetesPediatric Diabetes
Non-alcoholic fatty liver disease in pediatric type 2 diabetes: metabolic and histologic characteristics in 38 subjects
Pediatr Diabetes.
Newfield RS, Graves CL, Newbury RO, Schwimmer JB, Proudfoot JA, Say DS, Feldstein AE
doi: 10.1111/pedi.12798.
Diabetes - GeneralType 2 DiabetesObesity and Bariatric Surgery
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Diabetologia.
Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnström M, Moris L, Miliotis T, Forsberg GB, Risérus U, Lind L, Oscarsson J
doi: 10.1007/s00125-018-4675-2.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study
Diabetes Care.
Shore AC, Colhoun HM, Natali A, Palombo C, Khan F, Östling G, Aizawa K, Kennbäck C, Casanova F, Persson M, Gooding K, Gates PE, Looker H, Dove F, Belch J, Pinnola S, Venturi E, Kozakova M, Goncalves I, Kravic J, Björkbacka H, Nilsson J; SUMMIT Consortium
doi: 10.2337/dc18-0185.
Type 2 Diabetes
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
Diabetes Obes Metab.
Gastaldelli A, Repetto E, Guja C, Hardy E, Han J, Jabbour SA, Ferrannini E
doi: 10.1111/dom.13907.
Type 2 Diabetes
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Diabetologia.
Wanner C, Marx N
doi: 10.1007/s00125-
COMMENTED
Type 2 DiabetesObesity and Bariatric Surgery
The Novel Adipokine Gremlin 1 Antagonizes Insulin Action and is Increased in Type 2 Diabetes and NAFLD/NASH
★ 0
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes.
Hedjazifar S, Shahidi RK, Hammarstedt A, Bonnet L, Church C, Boucher J, Blüher M, Smith U
doi: 10.2337/db19-0701.
COMMENTED
Type 2 Diabetes
Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes
Diabetes.
Wittenbecher C, Ouni M, Kuxhaus O, Jähnert M, Gottmann P, Teichmann A, Meidtner K, Kriebel J, Grallert H, Pischon T, Boeing H, Schulze MB, Schürmann A
doi: 10.2337/db18-0620.
Type 2 Diabetes
Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study
Diabetologia.
Harris K, Oshima M, Sattar N, Würtz P, Jun M, Welsh P, Hamet P, Harrap S, Poulter N, Chalmers J, Woodward M
doi: 10.1007/s00125-020-05162-z.